Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:05 ET
|
Vaxart, Inc.
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus...
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
February 24, 2022 08:30 ET
|
Vaxart, Inc.
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses...
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
February 14, 2022 08:00 ET
|
Vaxart, Inc.
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference
January 04, 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron
December 16, 2021 08:00 ET
|
Vaxart, Inc.
Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide...
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
December 01, 2021 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s...
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021
November 23, 2021 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine...
Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
November 18, 2021 16:02 ET
|
Vaxart, Inc.
STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under...
Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases
November 16, 2021 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical...
Vaxart to Participate at Upcoming Conferences
November 11, 2021 16:01 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer,...